Human Metabolome Technologies Valuation

Q: What is the Fair Price of 6090 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

6090 (¥602) is trading above our estimate of [[fair value]] (¥570.45)

Is 6090 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6090 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6090 (¥602) is trading above our estimate of fair value (¥570.45)

Significantly Below Fair Value: 6090 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6090?

Key metric: As 6090 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 6090. This is calculated by dividing 6090's market cap by their current earnings.
What is 6090's PE Ratio?
PE Ratio	14.5x
Earnings	JP¥246.00m
Market Cap	JP¥3.58b

6090 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.7x
Enterprise Value/EBITDA	7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 6090's PE Ratio compare to its peers?

The above table shows the PE ratio for 6090 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	23.9x
4570 Immuno-Biological Laboratories	20.3x	n/a	JP¥4.7b
2183 Linical	30.6x	n/a	JP¥7.8b
7079 WDB coco	9.1x	n/a	JP¥8.7b
4880 CellSource	35.7x	30.1%	JP¥22.7b
6090 Human Metabolome Technologies	14.5x	n/a	JP¥3.6b

Price-To-Earnings vs Peers: 6090 is good value based on its Price-To-Earnings Ratio (14.5x) compared to the peer average (23.9x).

Price to Earnings Ratio vs Industry

How does 6090's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 6090 is good value based on its Price-To-Earnings Ratio (14.5x) compared to the Asian Life Sciences industry average (30.8x).

Price to Earnings Ratio vs Fair Ratio

What is 6090's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6090 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	14.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6090's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shionogi

JP¥1.8t

Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.

4507

JP¥2,104.50

-1.7%

-10.4%

Tsumura

JP¥366.2b

Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.

4540

JP¥4,855.00

1.1%

76.2%

ASKA Pharmaceutical HoldingsLtd

JP¥57.7b

Through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan.

4886

JP¥2,039.00

-2.1%

13.3%